<DOC>
	<DOCNO>NCT02624258</DOCNO>
	<brief_summary>Pilot open-label study estimate feasibility , safety efficacy intravenously administer , RNA electroporated autologous T cell express CD19 chimeric antigen receptor express tandem TCRζ 4-1BB ( TCRζ /4-1BB ) costimulatory domain ( refer `` RNA CART19 '' ) Hodgkin Lymphoma ( HL ) patient . Subjects treat IV administration RNA anti-CD19 CAR T cell total six dose 3 week .</brief_summary>
	<brief_title>Pilot Study Non-Viral , RNA-Redirected Autologous T Cells Patients With Refractory Relapsed Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Male female subject HL available curative treatment option ( autologous SCT ) limit prognosis ( several month &lt; 2 year survival ) currently available therapy enrol . HL biopsyproven relapse refractory disease unresponsive intolerant least one line standard salvage therapy ; Patients must evaluable disease radiologic imaging ( FDG PETCT FDG PETMRI ) within 42 day enrollment ; evaluable include assessable and/or measurable disease Age 18 24 year . Patients age 2224 enrol currently treat CHOP another pediatric facility/oncologist . Expected survival &gt; 12 week time screen Adequate organ function define : Renal function define : Creatinine clearance radioisotope GFR &gt; 60 mL/min/1.73 m2 OR Serum creatinine : &lt; 1.7mg/dL ( male subject ) &lt; 1.4mg/dL ( female subject ) ALT &lt; 5 time ULN age Total Bilirubin &lt; 2.0 mg/dl Must minimum level pulmonary reserve define ≤ Grade 1 dyspnea pulse oxygenation &gt; 94 % room air Patients relapse disease prior allogeneic SCT ( myeloablative nonmyeloablative ) eligible meet inclusion criterion Have active GVHD require immunosuppression Are 6 month transplant 6 ) Karnofsky performance status ≥ 50 screening Left Ventricular Shortening Fraction ( LVSF ) &gt; 28 % confirm echocardiogram , Left Ventricular Ejection Fraction ( LVEF ) &gt; 45 % confirm echocardiogram MUGA Signed write informed consent must obtain prior study procedure Successful T cell test expansion ( perform part inclusion criterion 3 subject meet enrollment criterion ) Pregnant lactate woman . The safety therapy unborn child know . Female study participant reproductive potential must negative serum pregnancy test enrollment . A urine pregnancy test perform within 48 hour RNA CART19 infusion . Uncontrolled active infection . Active hepatitis B hepatitis C infection . Any uncontrolled active medical disorder would preclude participation outline . HIV infection . Patients know active CNS involvement malignancy . Patients prior CNS disease effectively treat eligible provide treatment &gt; 4 week enrollment Patients complete remission evidence radiologic image disease . History allergy murine proteins History allergy hypersensitivity study product excipients ( human serum albumin , DMSO , Dextran 40 ) . AntiCD20 monoclonal antibody therapy within last 3 month , absence circulating B cell Unstable angina and/or myocardial infarction within 6 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>